Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CapeOX in elderly patients with untreated metastatic gastric cancer
jRCTs051180126Phase 2Completed
- Sponsor
- Yakult Honsha
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in gastric cancer (GC), sponsored by Yakult Honsha. Primary endpoint: Overall survival. Started Sep 2016; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs051180126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180126.